A. Pike

发表

A novel method for preventing non-specific binding in equilibrium dialysis assays using Solutol® as an additive.

A. Srivastava, K. Fenner, B. Williamson, 2020, Journal of pharmaceutical sciences.

Designing Peripheral Drugs for Minimal Brain Exposure

P. Bungay, S. Bagal, A. Pike, 2015 .

Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist

Sandra M. Sanabria-Bohórquez, G. Bormans, K. Van Laere, 2011, Journal of psychopharmacology.

Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.

Peng-Fei Wang, J. Patel, B. Barlaam, 2020, Bioorganic & medicinal chemistry letters.

Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs

B. Jones, A. Pike, Roshini Markandu, 2021, Drug Metabolism and Disposition.

RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708

G. Dawson, R. Mckernan, J. Atack, 2006, Drug Metabolism and Disposition.

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.

P. A. Bradley, Brian E Marron, Ian K Gurrell, 2017, Journal of medicinal chemistry.

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.

A. Ferguson, L. Drew, W. Shao, 2020, Journal of medicinal chemistry.

Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective.

D. Mcginnity, B. Williamson, S. Harlfinger, 2020, Drug discovery today.

Optimization of a Series of Potent, Selective and Orally Bioavailable SYK Inhibitors.

David M. Wilson, Peng-Fei Wang, S. Fawell, 2009, Bioorganic & medicinal chemistry letters.

ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)

N. Hariparsad, D. Ramsden, D. Mcginnity, 2022, Xenobiotica; the fate of foreign compounds in biological systems.

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper

M. O’Connor, S. Fawell, Glen Hawthorne, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Design and Identification of a Novel, Functionally Subtype Selective GABAA Positive Allosteric Modulator (PF-06372865).

R. M. Owen, Chan Woo Huh, Lishuang Cao, 2019, Journal of medicinal chemistry.

Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF‐06372865

Donal N. Gorman, R. M. Owen, J. V. van Gerven, 2018, British journal of pharmacology.

The in vivo properties of pagoclone in rat are most likely mediated by 5′-hydroxy pagoclone

G. Dawson, R. Mckernan, J. Atack, 2006, Neuropharmacology.

Highly potent and selective NaV1.7 inhibitors for use as intravenous agents and chemical probes.

Brian E Marron, Neil A Castle, Rubben Torella, 2017, Bioorganic & medicinal chemistry letters.

Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders

Sara C. Humphreys, Donglu Zhang, C. Rynn, 2023, Drug Metabolism and Disposition.

The role of organic anion‐transporting polypeptides and formulation in the clearance and distribution of a novel Nav1.7 channel blocker

E. Tseng, A. Pike, Neil J. Flanagan, 2018, Biopharmaceutics & drug disposition.

Structural and Physicochemical Features of Oral PROTACs.

A. Pike, Amber Y. S. Balazs, I. Terstiege, 2024, Journal of medicinal chemistry.